Mingjun Rui
YOU?
Author Swipe
Cost-effectiveness of maternal vaccination against respiratory syncytial virus in Hong Kong: a decision-analytical analysis Open
Year-round and seasonal maternal RSV vaccination strategies saved QALYs at a higher cost from a societal perspective in Hong Kong. The cost-effectiveness acceptance of both strategies is highly dependent on the RSV vaccine cost.
Cost-Effectiveness Analysis of Fecal Microbiota Transplantation for Patients with Irritable Bowel Syndrome Open
Introduction: Studies have demonstrated clinical benefits of fecal microbiota transplantation (FMT) for treatment of irritable bowel syndrome (IBS). This study aimed to evaluate the cost-effectiveness of FMT versus standard drug treatment …
Cost‐Effectiveness Analysis of Nirsevimab for Respiratory Syncytial Virus Disease Prevention in Newborns of Hong Kong Open
Background Nirsevimab, a long‐acting monoclonal antibody, was shown to prevent respiratory syncytial virus (RSV) infections in newborns. We evaluated the cost‐effectiveness of nirsevimab strategies for newborns from the societal perspectiv…
NMAsurv: An R Shiny application for network meta-analysis based on survival data Open
Network meta-analysis (NMA) is becoming increasingly important, especially in the field of medicine, as it allows for comparisons across multiple trials with different interventions. For time-to-event data, that is, survival data, traditio…
Supplementary Table S1 from Novel Noninvasive Tests for Colorectal Cancer Screening – A Cost-Effectiveness Analysis Open
Supplementary Table S1 shows clinical inputs for model natural history of CRC
Data from Novel Noninvasive Tests for Colorectal Cancer Screening – A Cost-Effectiveness Analysis Open
Background:To compare cost-effectiveness of three novel noninvasive tests [multitarget stool RNA (mt-sRNA), multitarget stool DNA 2.0, and cell-free DNA] with guideline-recommended tests for colorectal cancer screening from payer’s perspec…
Supplementary Figure S1 from Novel Noninvasive Tests for Colorectal Cancer Screening – A Cost-Effectiveness Analysis Open
Supplementary Figure S1 shows simplified Markov model for natural history of CRC
Sup Materials and Methods from Novel Noninvasive Tests for Colorectal Cancer Screening – A Cost-Effectiveness Analysis Open
Supplementary Materials and Methods
Supplementary Table S2 from Novel Noninvasive Tests for Colorectal Cancer Screening – A Cost-Effectiveness Analysis Open
Supplementary Table S2 shows base-case analysis of all strategies versus next costly strategy
Supplementary Figure S2 from Novel Noninvasive Tests for Colorectal Cancer Screening – A Cost-Effectiveness Analysis Open
Supplementary Figure S2a-b shows cumulative number of CRC cases and CRC deaths for model validation
View article: Cost-effectiveness of combining AI and cfDNA with LDCT for lung cancer screening in China: a modelling study
Cost-effectiveness of combining AI and cfDNA with LDCT for lung cancer screening in China: a modelling study Open
Background: Lung cancer remains one of the leading causes of cancer-related mortality in China, where early detection through screening is critical for improving survival rates. Low-dose computed tomography (LDCT) has proven effective for …
Health Economic Evaluations of Circulating Tumor <span>DNA</span> Testing for Cancer Screening: Systematic Review Open
Background Cancer detection remains a significant global healthcare challenge, and circulating tumor DNA (ctDNA) is a biomarker for noninvasive cancer screening. Objective This systematic review aimed to describe health economic evaluation…
HRR deficiency-guided use of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer: a cost-effectiveness analysis Open
Background: Talazoparib plus enzalutamide showed significant improvement of progression-free survival in metastatic castration-resistant prostate cancer (mCRPC) patients with alterations in homologous recombination repair (HRR) genes. Obje…
Optimizing covariate selection and results inference in anchored matched adjusted indirect comparison method Open
Indirect comparison methods become particularly prominent in pharmacoeconomic evaluations. This study delves into the anchored matched adjusted indirect comparison (MAIC) method, spotlighting the challenges of selecting appropriate covaria…
Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC Open
Background and objective Sintilimab has superior efficacy and safety in patients with advanced or metastatic squamous non-small cell lung cancer (NSCLC), but its cost-effectiveness in China is unclear. This study is to evaluate the cost-ef…
Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China Open
Sintilimab + chemotherapy is a cost-effective option compared with camrelizumab + chemotherapy as the first-line treatment for locally advanced or metastatic nonsquamous NSCLC in China.
The Relationship Between Short-Term Surrogate Endpoint Indicators and mPFS and mOS in Clinical Trials of Malignant Tumors: A Case Study of Approved Molecular Targeted Drugs for Non-Small-Cell Lung Cancer in China Open
Objective: Due to the initiation of the priority review program in China, many antitumor drugs have been approved for marketing based on phase II clinical trials and short-term surrogate endpoint indicators. This study used approved target…
Will the Inducing and Maintaining Remission of Non-biological Agents and Biological Agents Differ for Crohn's Disease? The Evidence From the Network Meta-Analysis Open
Background: Several drugs currently are available for the treatment of Crohn's disease, including non-biological agents such as anti-inflammatory agents, steroids, immunosuppressive agents, and biologic agents such as anti-tumor necrosis f…
Health-Related Quality of Life in Patients With Different Diseases Measured With the EQ-5D-5L: A Systematic Review Open
Background: The EQ-5D-5L is a generic preference-based questionnaire developed by the EuroQol Group to measure health-related quality of life (HRQoL) in 2005. Since its development, it has been increasingly applied in populations with vari…
Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2– Advanced or Metastatic Breast Cancer: A US Payer Perspective Open
Introduction: This study evaluated the cost-effectiveness of abemaciclib plus fulvestrant (ABE + FUL) vs. palbociclib plus fulvestrant (PAL + FUL), ribociclib plus fulvestrant (RIB + FUL) and fulvestrant monotherapy (FUL) as second-line tr…
Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US Open
Introduction: This study evaluated the cost-effectiveness of atezolizumab + chemotherapy vs. chemotherapy as first-line treatment for extensive-stage small-cell lung cancer (SCLC) in the United States (US). Methods: The three health states…
Economic Evaluation of Rituximab + Recombinant Human Thrombopoietin vs. Rituximab for the Treatment of Second-Line Idiopathic Thrombocytopenic Purpura in China Open
Objective: This study aimed to compare the economic evaluation of recombinant human thrombopoietin+rituximab (rhTPO + RTX) vs. RTX as second-line treatment for adult patients with immunologic thrombocytopenic purpura in China. Methods: The…